LitAlert ~~ GeneLit.com

    • Preclinical and clinical evidence of Lurbinectedin in ovarian cancer: current status and future perspectives.
    • Musacchio L, Cicala CM, Salutari V, Camarda F, Carbone MV, Ghizzoni V, Giudice E, Nero C, Perri MT, Ricci C, Tronconi F, Scambia G, Lorusso D.
    • Front Oncol. 2022 Feb 1;10:831612. doi: 10.3389/fonc.2022.831612.
    • Case series: 'Aggressive HRD-positive colorectal cancer related to a BRCA1 pathogenic germline variant in young patients'.
    • Freire Chadrina MV, Martin M, Thissen R, Van Marcke C, Segers K, Sépulchre E, Leroi N, Lété C, Fasquelle C, Radermacher J, Gokburun Y, Collignon J, Sacré A, Josse C, Palmeira L, Vincent B.
    • Front Oncol. 2022 Feb 1;10:835581. doi: 10.3389/fonc.2022.835581.
    • Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
    • Trillsch F, Mahner S, Ataseven B, Asher R, Aryal N, Dubot C, Clamp A, Penson RT, Oza A, Amit A, Huzarski T, Casado A, Scambia G, Friedlander M, Colombo N, Fujiwara K, Sonke GS, Denys H, Lowe ES, Lee CK, Pujade-Lauraine E.
    • Gynecol Oncol. 2022 Jan 31:S0090-8258(22)00050-6. doi: 10.1016/j.ygyno.2022.01.024. Epub ahead of print.
    • Invasive Breast Carcinoma: Rare Clinical Presentation in a Male Patient.
    • Hanna M, Solly M.
    • Cureus. 2021 Dec 20;13(12):e20547. doi: 10.7759/cureus.20547.